Methoxetamine: From drug of abuse to rapid-acting antidepressant

被引：28

作者：

Coppola, M. ^{[1
]}

Mondola, R. ^{[2
]}

机构：

[1] ASL CN2, Dept Addict, I-12051 Alba, CN, Italy

[2] ASL CN1, Dept Mental Hlth, I-12037 Saluzzo, CN, Italy

来源：

MEDICAL HYPOTHESES | 2012年 / 79卷 / 04期

关键词：

MAJOR DEPRESSIVE DISORDER; D-ASPARTATE ANTAGONIST; RESISTANT BIPOLAR DEPRESSION; STAR-ASTERISK-D; ELECTROCONVULSIVE-THERAPY; ALCOHOL DEPENDENCE; SIGMA-RECEPTORS; CHRM2; GENE; RAT-BRAIN; KETAMINE;

D O I：

10.1016/j.mehy.2012.07.002

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Methoxetamine is a dissociative anaesthetic showing pharmacodynamic similarities with its analogue ketamine, a medication with demonstrated rapid-acting antidepressant effects. Like ketamine and other arylcyclohexylamine compounds, methoxetamine is thought to be both a noncompetitive NMDA receptor antagonist and a dopamine reuptake inhibitor. Furthermore, it acts as an agonist at dopamine D2, serotonin 5HT2, muscarinic cholinergic, sigma-1, opioid mu and k receptors. The hypothesis is that methoxetamine can produce rapid antidepressant effects in patients with resistant and non-resistant unipolar and bipolar depression. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：504 / 507

页数：4

共 50 条

[31] Ozonized autohaemotransfusion could be a potential rapid-acting antidepressant medication in elderly patients
Coppola, Ludovico
Luongo, Carlo
Pastore, Agostino
Masciello, Claudia
Parascandola, Rita Rosaria
Mastrolorenzo, Luigia
Grassia, Antonio
Coppola, Antonino
De Biase, Maria
Lettieri, Biagio
Gombos, Giorgio
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2010, 25 (02) : 206 - 211
[32] The in vivo pharmacodynamic and biopharmaceutical characterization of a novel dual mechanism, rapid-acting antidepressant
Talbot, Jeffery N.
Rawlins, David B.
Movahedi, Fereshteh
Zhudeva, Mariya Y.
Vo, Annh
Phan, Julie
Dorigatti, Jonathan
Velazquez, Gabriel
Kirsh, Robert D.
Yellepeddi, Venkatta K.
FASEB JOURNAL, 2017, 31
[33] Rapid-acting oral drug (Auvelity) for major depressive disorder
Khabir, Yumna
Hashmi, Mahnoor Rehan
Asghar, Adam Ali
ANNALS OF MEDICINE AND SURGERY, 2022, 82
[34] The Revolution in Rapid-Acting Antidepressants
Sanacora, Gerard
Duman, Ronald S.
BIOLOGICAL PSYCHIATRY, 2013, 73 (12) : 1123 - 1124
[35] Rapid-Acting Insulin Analogs
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2009, 51 (1327): : 98 - 98
[36] Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Johnston, Jenessa N.
Kadriu, Bashkim
Allen, Josh
Gilbert, Jessica R.
Henter, Ioline D.
Zarate, Carlos A., Jr.
NEUROPHARMACOLOGY, 2023, 226
[37] Role of a VGF/BDNF/TrkB Autoregulatory Feedback Loop in Rapid-Acting Antidepressant Efficacy
Cheng Jiang
Wei-Jye Lin
Stephen R. Salton
Journal of Molecular Neuroscience, 2019, 68 : 504 - 509
[38] Decoding the Mechanism of Action of Rapid-Acting Antidepressant Treatment Strategies: Does Gender Matter?
Herzog, David P.
Wegener, Gregers
Lieb, Klaus
Mueller, Marianne B.
Treccani, Giulia
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (04):
[39] Ketamine and the neurobiology of depression: Toward next- generation rapid-acting antidepressant treatments
Krystal, John H.
Kaye, Alfred P.
Jefferson, Sarah
Girgenti, Matthew J.
Wilkinson, Samuel T.
Sanacora, Gerard
Esterlis, Irina
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (49)
[40] No Meaningful Opioid Abuse Liability of REL-1017 (Esmethadone; D-Methadone), a Rapid-Acting Antidepressant in Clinical Development: A Human Abuse Potential Study
Henningfield, Jack
Apseloff, Glen
Gorodetsky, Charles
Pappagallo, Marco
Shram, Megan
De Martin, Sara
Fant, Reginald
Vocci, Frank
Sapienza, Frank
Kosten, Thomas
Huston, Jeff
Buchhalter, August
Ashworth, Judy
Lanier, Ryan
Folli, Franco
Traversa, Sergio
Inturrisi, Charles E.
Manfredi, Paolo L.
NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 241 - 242

← 1 2 3 4 5 →